Bulk Inquiry
OSI 906
- Linsitinib
Axon 1702
CAS:
867160-71-2
Purity:
99%
- Soluble in DMSO
- MF: C26H23N5O
- MW: 421.49
Description
OSI 906 is a highly potent, orally efficacious and ATP-competitive IGF-1R/insulin receptor inhibitor with IC50 values of 35 nM for IGF-1R and 75 nM for IR.
IGF-1R and insulin receptor signaling regulate growth, metabolism, survival and resistance pathways in cancer cells. OSI 906 is useful for studying dual IGF-1R/IR blockade and metabolic growth factor signaling.
Key Features
- Dual ATP-competitive IGF-1R and IR inhibitor
- IC50: 35 nM for IGF-1R and 75 nM for insulin receptor
- Orally active receptor tyrosine kinase pharmacology
- Targets growth factor survival signaling
Applications
- IGF-1R/IR signaling research
- Cancer growth and survival assays
- Metabolic signaling studies
- Kinase inhibitor selectivity profiling
More Information
| Parent CAS No. | 867160-71-2 |
|---|---|
| Chemical Name | 3-[8-Amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutanol |
| MFCD | N.A. |
| Short Description | IGF1R inhibitor |
References
- MJ Mulvihill et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Fut. Med. Chem. 2009, 1(6), 1153-1171.
- CP Carden et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28,15s
- V. M. Macaulay et al. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced (...). J. Clin. Oncol. 2010, 28,15s
Other Categories
Get a Quote for
Loading...